CentryMed (Drug Discovery) Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 47

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Financing Rounds
  • 10

CentryMed (Drug Discovery) General Information

Description

Developer of antibody-based therapeutic drugs designed for targeted treatment of malignant tumors and autoimmune diseases. The company's technology utilizes four generations of platforms, including multi-channel antibody discovery, H-form bispecific T-cell engagers, protease-activated bispecific T-cell engagers, and multifunctional logic-gated T-cell engagers, providing pharmaceutical researchers with monoclonal and bispecific antibodies, enabling the development of targeted therapies for complex diseases with improved efficacy and safety profiles.

Contact Information

Ownership Status
In IPO Registration
Financing Status
Private Equity-Backed
Corporate Office
  • Room 2008, 20th Floor, Huachuang Building
  • Number 511 Jianye Road, Changhe Street, Binjiang District
  • Hangzhou, Zhejiang 310051
  • China
+86 0571
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Room 2008, 20th Floor, Huachuang Building
  • Number 511 Jianye Road, Changhe Street, Binjiang District
  • Hangzhou, Zhejiang 310051
  • China
+86 0571

CentryMed (Drug Discovery) Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CentryMed (Drug Discovery) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CentryMed (Drug Discovery)‘s full profile, request access.

Request a free trial

CentryMed (Drug Discovery) Patents

CentryMed (Drug Discovery) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025035356-A1 Antibodies against dll3 and uses thereof Inactive 14-Aug-2023
WO-2025010538-A1 Antibodies against gucy2c and uses thereof Inactive 07-Jul-2023
WO-2024254778-A1 Antibodies against cll1 and uses thereof Inactive 14-Jun-2023
WO-2024254757-A1 Bispecific antibodies against folr1 and uses thereof Inactive 13-Jun-2023
WO-2024168588-A1 Egfr and lag3 dual targeted bispecific antibody and uses thereof Inactive 15-Feb-2023 A61P35/00
To view CentryMed (Drug Discovery)’s complete patent history, request access »

CentryMed (Drug Discovery) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CentryMed (Drug Discovery) Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CentryMed (Drug Discovery)‘s full profile, request access.

Request a free trial

CentryMed (Drug Discovery) FAQs

  • When was CentryMed (Drug Discovery) founded?

    CentryMed (Drug Discovery) was founded in 2017.

  • Where is CentryMed (Drug Discovery) headquartered?

    CentryMed (Drug Discovery) is headquartered in Hangzhou, China.

  • What is the size of CentryMed (Drug Discovery)?

    CentryMed (Drug Discovery) has 47 total employees.

  • What industry is CentryMed (Drug Discovery) in?

    CentryMed (Drug Discovery)’s primary industry is Drug Discovery.

  • Is CentryMed (Drug Discovery) a private or public company?

    CentryMed (Drug Discovery) is a Private company.

  • What is CentryMed (Drug Discovery)’s current revenue?

    The current revenue for CentryMed (Drug Discovery) is .

  • How much funding has CentryMed (Drug Discovery) raised over time?

    CentryMed (Drug Discovery) has raised $81.6M.

  • Who are CentryMed (Drug Discovery)’s investors?

    Shenzhen GTJA Investment Group, Hainan Xinguoxing Private Equity Fund Management, Hangzhou Bejia Investment Management, Hangzhou Hi-Tech Financial Investment Group, and Hangzhou Tailong Venture Capital Partnership are 5 of 13 investors who have invested in CentryMed (Drug Discovery).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process